Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

INTRODUCTION: In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; ClinicalTrials.gov number NCT01994889), tafamidis reduced the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) by 30% versus placebo. Median overall survival was not ac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cardiol Ther
Autores principales: Li, Benjamin, Alvir, Jose, Stewart, Michelle
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7584686/
https://ncbi.nlm.nih.gov/pubmed/32524297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40119-020-00179-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares